
via Massachusetts General Hospital
Key Takeaways
- Parathyroid hormone–based medications can stimulate bone formation to treat osteoporosis but are only effective when administered by injection
- Researchers have now identified an oral compound that influences components of the parathyroid hormone signaling pathway to increase bone formation and bone mass in mice
- The investigators are currently working to optimize and develop this compound into a new therapy for patients
Parathyroid hormone can stimulate bone formation, and analogs of the hormone are often prescribed to patients with osteoporosis; however, these medications are only effective when administered by daily injection.
A team led by investigators at Massachusetts General Hospital (MGH) recently identified a promising compound that influences components of the parathyroid hormone signaling pathway and that, when given orally to mice, increases bone mass. The group’s discovery, which is published in PNAS, might lead to a new, more convenient drug for preventing and treating osteoporosis.
“Currently there are no orally available medications for osteoporosis that stimulate bone formation. We sought to develop such medications based upon our detailed understanding of the pathways that normally govern bone production,” says senior author Marc Wein, MD, PhD, an endocrinologist at MGH and an Assistant Professor of Medicine at Harvard Medical School.
The pathway that involves parathyroid hormone inhibits salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3), which are enzymes with roles in the regulation of bone growth and remodeling.
Wein and his colleagues generated a novel structural model of these enzymes and then used advanced methods including structure-based drug design and iterative medicinal chemistry to identify a compound that potently inhibits SIK2 and SIK3. This compound, termed SK-124, had parathyroid hormone–like effects when given to cells and, most importantly, when fed to mice. In mice, oral treatment once a day for three weeks increased blood levels of calcium and vitamin D and also boosted bone formation and bone mass without evidence of short-term toxicity.
“Based on these findings, we propose that small molecules like SK-124 might represent ‘next generation’ oral bone building therapies for osteoporosis,” says Wein. “We are currently collaborating with a pharmaceutical company—Radius Health, Inc.—to further optimize and develop this compound into a treatment for patients.”
Original Article: New Oral Compound Developed by Mass General Researchers May Help Prevent and Treat Osteoporosis
More from: Massachusetts General Hospital
The Latest Updates from Bing News
Go deeper with Bing News on:
Osteoporosis treatment
- Amgen: Relative Valuation Remains Unattractive
Amgen Inc. ( NASDAQ:AMGN) is an American biopharmaceutical company specializing in the development and commercialization of medicines aimed at treating patients with cardiovascular disease, cancer, ...
- Global Anti-Osteoporosis Therapy and Fracture Healing Industry, according to FMI, are forecasted to have a 4.8% CAGR between 2023 and 2033
As the healthcare landscape continues to evolve, the forecast for the global anti-osteoporosis therapy and fracture healing industry shines bright with a projected valuation of US$ 22,427.6 million by ...
- FDA approves Ambio’s generic version of osteoporosis treatment
The US Food and Drug Administration (FDA) has granted approval for Ambio’s generic version of Forteo for the treatment of osteoporosis.
- Hip fractures: A looming healthcare crisis
With the number of hip fractures projected to double by 2050, Dr Philippe Halbout, CEO of the International Osteoporosis Foundation, calls for timely action, including post-fracture care to prevent co ...
- 59 Best Doctors for Osteoporosis Treatment near Adhyatmic Nagar, Ghaziabad
Osteoporosis is a condition affecting the bones that makes them weak and fragile. The disease is generally diagnosed when one of the bones breaks due to minor or no external injury. This condition ...
Go deeper with Bing News on:
Osteoporosis
- Amgen: Relative Valuation Remains Unattractive
Amgen Inc. ( NASDAQ:AMGN) is an American biopharmaceutical company specializing in the development and commercialization of medicines aimed at treating patients with cardiovascular disease, cancer, ...
- Can drinking milk cause osteoporosis? A study-based analysis
The debate over whether milk causes osteoporosis has recently intensified, challenging the traditional view of milk as a beneficial source of calcium for bone health.
- Global Anti-Osteoporosis Therapy and Fracture Healing Industry, according to FMI, are forecasted to have a 4.8% CAGR between 2023 and 2033
As the healthcare landscape continues to evolve, the forecast for the global anti-osteoporosis therapy and fracture healing industry shines bright with a projected valuation of US$ 22,427.6 million by ...
- FDA approves Ambio’s generic version of osteoporosis treatment
The US Food and Drug Administration (FDA) has granted approval for Ambio’s generic version of Forteo for the treatment of osteoporosis.
- Can a lot of calcium supplements help to keep osteoporosis at bay? Expert debunks 6 myths
Does drinking milk and regularly exercising reduce osteoporosis risk? Can opting for lot of calcium supplements keep osteoporosis at bay? Expert debunks 6 myths ...